References

  1. Aram V, Bakris GI, Black HR, Cushman WC, Green LA, Izzo Jr JI et al. The seventh Report of the Joint national committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure, JAMA. 2003; 289(19):2560-71.

  2. Borel J-P. Maladie des vaisseaux: pression artérielle, artériosclérose, pp 93-11 In Biochimie pour le clinicien, Mécanisme moléculaires et chimiques à l'origine des maladies, Maclean Hunter, Editions Frison-Roch, paris. 1999 ; 394p.

  3. Bin Zhou, James Bentham, Mariachiara Di Cesare, Honor Bixby, Goodarz Danaei, Melanie CowanJ et al. worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19,1 million participants (NCD Risk Factor collaboration). Lancet. 2017; 389(10064):37-55. Google Scholar

  4. Lawes CM, Vander HS, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet. 2008; 371(9623):1513-8. PubMed | Google Scholar

  5. Calixte Haba Hebane Guehi. Facteurs de risque cardiovasculaire chez les patients avant et après initiation des antirétroviraux en Afrique Sub-Saharienne, expérience de l'Essai Temprano ANRS). Université de Bordeaux. 2017 ;These de 3e cycle. Google Scholar

  6. Amah G, Lévy BI. Particularités de l'hypertension artérielle du sujet noir-africain. Sang Thrombose Vaisseaux (STV). 2007; 19(10):519-25. Google Scholar

  7. Steven van de Vijver, Akinyi H, Oti S, Kyobutungi C. Incidence des maladies non transmissibles (MNT) et des maladies tropicales négligées (MTN) sur le développement en Afrique: Etat de l'hypertension artérielle-CARMMA. CAMH/Exp/6(VI) iii. 201;1-14.

  8. Spence JD, Rayner BL. Hypertension in Blacks Individualized Therapy Based on Renin/Aldosterone Phenotyping. Hypertension. 2018; 72(2):263-69. PubMed | Google Scholar

  9. Diallo BA. Profil épidémiologique de l'HTA en milieu hospitalier à Bamako. Méd Afr Noire. 1994; 41(2):103-5. Google Scholar

  10. Menta I, Ba HO, Sanogo KM. Hypertension (HTA) among young people of 18 to 35 years old in cardiology department of Gabriel Touré university teaching hospital. World Journal of Cardiovascular Diseases. 2018; 8(1):11-17. Google Scholar

  11. Koopman JJE, Bodegom DV, Jukema JW, Westendorp RGJ. Risk of cardiovascular disease in a traditional African population with a high infectious load: a population-based study. PLoS One. 2012; 7(10):e46855. PubMed | Google Scholar

  12. Dembélé M.La place de l'hypertension artérielle dans le milieu spécialisé cardiologique du chu Gabriel Touré. Thèse Med, Bamako. 2011;n°11M25. Google Scholar

  13. Peynet J, Dehoux M, Lefèvre G, Philip I. Marqueurs de dysfonctionnement cardiaque, pp 183-210. In Beau deux J-L, Geneviève Durand. Biochimie médicale, marqueurs actuels et perspectives(Médecines Sciences Publication, Lavoisier, Paris). 2013; 2è éd, 607p.

  14. Livio F, Biollaz J, Burnier M. Estimation de la fonction rénale par l'équation MDRD: intérêt et limites pour l'adaptation des doses de médicaments. Rev Med Suisse. 2008; 4(181):2596-600. PubMed | Google Scholar

  15. Dulac M, Sanandedji E, Zimmer L. Prépa-Pharma Biochimie, catégorie pharmacologie. DeBoeck Supérieur. 2018; 1ere éd: 256p.

  16. Gervais R, Willoquet G. Guide pharmaco, étudiants et professionnels en soins infirmiers.Lammarre. 2017; 12e édition: 1753p.

  17. Mark JM Lacey JM, Casetta B, Rinaldo P. Method for the determination of total homocysteine in plasma and urine by stable isotope dilution and electrospray tandem mass spectrometry. Clin Chemistry. 1999; 45(9):1517-22. PubMed | Google Scholar

  18. Carrère P. HTA, obésité, précarité en Guadeloupe l'enquête Constant. Univ Toulouse III, Paul Sébatier Thèse de med. 2010; 162p. Google Scholar

  19. Adoubi KA, Nguetta R, Yangni-angate KH, Diby KF, Adoh AM. Aspects épidémiologiques, cliniques et thérapeutiques de l'hypertension artérielle à Bouaké. Cahier Santé publique. 2006; 5(2):28-35.

  20. Menta I, Traoré D, Ba HO, Diall IB, Coulibaly S, Touré K et al. La protéinurie chez l'hypertendu dans le service de cardiologie du CHU Gabriel Touré. Mali médical. 2015; Tome 30(1):7-10. PubMed | Google Scholar

  21. Kaba ML, Balde MD, Bah AO, Diallo A, Beavogui M, Toure S et al. Evaluation de l'atteinte rénale au cours de l'hypertension artérielle de l'adulte à Conakry. Mali Médical. 2005; Tome 20(3):2-4. PubMed

  22. Pathak A, Rouet P, Despas F, Jourdan G, Verwaerde P, Galinier M et al. Obésité et hypertension artérielle: épidémiologie, physiopathologie et prise en charge. mt cardio. 2007; 3(3):169-77. Google Scholar

  23. Damorou F, Baragou S, Pio M, Afassinou YM, N'da NW, Pessinaba S et al. Morbidité et mortalité hospitalière des maladies cardiovasculaires en milieu tropical: exemple d'un centre hospitalier à Lomé (Togo). Pan Afr Med J. 2014; 17:62. PubMed | Google Scholar

  24. Becquey E, Savy M, Danel P, Dabiré HB, Tapsoba S, Martin-Prével Y. Dietary patterns of adults living in Ouagadougou and their association with overweight. Nut J. 2010; 9(13):1-10. PubMed | Google Scholar

  25. Baszczuk A, Kopczynski Z. Hyperhomocysteinemia in patients with cardiovascular disease. Postepy Hig Med Dosw. 2014;68:579-589. PubMed | Google Scholar

  26. Malinow MR, Bostom AG, Krauss RM. Homocysteine, diet and cardiovascular diseases. American Heart Association, circulation. 1999; 99(1):178-182. PubMed | Google Scholar

  27. Djuric D, Jakovljevic V, Rasic-Markovic A, Djuric A, O Stanojlovic. Homocysteine, Folic Acid and Coronary Artery Disease: possible impact on prognosis and therapy. Indian J Chest Dis Allied Sci. 2008; 50(1):39-48. PubMed | Google Scholar

  28. Chang Y, Li Y, Guo X, Chen Y, Dai D, Sun Y. The prevalence of hypertension accompanied by high Homocysteine and its risk factors in a rural population: a cross-sectional study from northeast China. Int J Environ Res Public Health. 2017; 14(4):2-16. PubMed | Google Scholar

  29. Han L, Ma W, Sun D, Heianza Y, Wang T, Zheng Y et al. Genetic variation of habitual coffee consumption and glycemic changes in response to weight-loss diet intervention: the preventing overweight using novel dietary strategies (POUNDS LOST) trial. Am J Clin Nut. 2017; 106(5):1321-1326. PubMed | Google Scholar

  30. Amouzou EK, Chabi NW, Adjalla CE, Rodriguez-Guéant RM, Feillet F, Villaume C et al. High prevalence of hyperthomocysteinemia related to folate deficiency and the 677CT mutation of the gene encoding methylene tetrahydro-folate reductase in coastal West Africa. Am J Clin Nutr. 2004; 79(4):619-624. PubMed | Google Scholar

  31. Grunitzky EK, Balogou AAK, Barque-Barry R, Kombate D, Amouzou EK. Homocystéinémie et accidents vasculaires cérébraux ischémiques au CHU campus de Lomé. Afr J of Neuro Sci. 2008; 27(2):3-9. Google Scholar

  32. Nakagawa O, Yoshimasa T, Nakao K. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy: evidence for brain natriuretic peptide as an “emergency” cardiac hormone against ventricular overload. J Clin Invest.1995; 96(3):1280-1287. Google Scholar

  33. Clerico A, Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides. Clin Chem. 2004 ;50(1):33-50. PubMed | Google Scholar

  34. Cleland JGF, McMurray JJV, Kjekshus J, Cornel JH, Dunselman P, Fonseca C et al. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from corona (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol. 2009; 54(20):1850-59. Google Scholar

  35. Emberson JR, Ng LL, Armitage J, Bowman L, Parish S, Collins R. N-terminal pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20536 patients in the MRC/BHF heart protection study. J Am Coll Cardiol. 2007; 49(3),311-319. PubMed | Google Scholar

  36. Olsen MH, Wachtella K, Nielsen OW, Hall C, Wergeland R, Ibsen H et al. N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a life substudy. J Hypertens. 2006; 24(8):1531-9. PubMed | Google Scholar

  37. Galinier M, Lambert G. NT-ProBNP: l'ange gardien de l'insuffisant cardiaque? Cahier 2. 2015; 1083:28p.

  38. Paget V, Legedz L, Gaudebout N, Girerd N, Bricca G, Milon H et al. N-terminal pro-brain natriuretic peptide: a powerful predictor of mortality in hypertension. hypertension. 2011; 57(4):702-709. PubMed | Google Scholar

  39. Gaskins AJ, Wilchesky M, Mumford SL, Whitcomb BW, Browne RW, Wactawski-Wende J. Endogenous reproductive hormones and C-reactive Protein across the menstrual cycle. Am J Epidemiol. 2012; 175(5):423-431. PubMed | Google Scholar

  40. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-Reactive Protein and the risk of developing hypertension. JAMA. 2003; 290(22):2945-2951. PubMed | Google Scholar

  41. Park CS, Ihm SH, Yoo KD, Kim DB, Lee JM, Kim HY et al. Relation between c-reactive protein, homocysteine levels, fibrinogen, and lipoprotein levels and leukocyte and platelet counts, and 10-year risk for cardiovascular disease among healthy adult in the USA. Am J Cardiol. 2010; 105(9):1284-1288. Google Scholar

  42. Tatasciore A, Zimarino M, Renda G, Zurro M, Soccio M, Prontera C et al. Awake blood pressure variability, inflammatory markers and target organ damage in newly diagnosed hypertension. Hypertens Res. 2008; 31(12):2137-2146. PubMed | Google Scholar

  43. Ahmed S, Hu R, Leete J, Layton AT. Understanding sex differences in long-term blood pressure regulation: insights from experimental studies and computational modeling. Am J Physiol Heart Circ Physiol. 2019 Mar 15; 316(5):H1113-H1123. PubMed